Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.517 -0.063 (-1.76%)
Streaming Delayed Price Updated: 2:31 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,429,556
Open 3.600
Bid (Size) 3.510 (21,800)
Ask (Size) 3.520 (20,200)
Prev. Close 3.580
Today's Range 3.500 - 3.720
52wk Range 3.490 - 12.36
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
This $4 Stock Could Be Your Ticket to Millionaire Status ↗
It's a potential game-changing technology. The company just needs to prove to the world that it works well enough. 
Via The Motley Fool
Topics Artificial Intelligence

Performance

YTD
-16.3%
-16.3%
1 Month
-25.2%
-25.2%
3 Month
-18.8%
-18.8%
6 Month
-37.6%
-37.6%
1 Year
-57.8%
-57.8%

More News

Read More
News headline image
Harvard’s PopEVE AI Cracks the Code of Rare Diseases: Ending the ‘Diagnostic Odyssey’ for Millions
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Forget 2025: These 2 Growth Stocks Could Soar in 2026 ↗
Via The Motley Fool
News headline image
Can This Beaten-Down AI Stock Bounce Back in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 AI Stocks to Buy in 2026, and 1 to Avoid ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
Via TokenRing AI
Topics Artificial Intelligence
News headline image
From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood’s Strategic Pivot: Ark Invest Trims Tesla Holdings to Fuel AI and Crypto Bets Ahead of 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…
Via AB Newswire
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why ↗
Via Benzinga
News headline image
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
Why Recursion Pharamaceuticals Topped the Market Today ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jim Cramer: This Health Care Stock Has Been 'Horrendous' ↗
Via Benzinga
News headline image
10 AI Stocks Worth Buying Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 3.517
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 02/13/26 02:31 PM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 592.35M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 592M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.